Trial Profile
Combination therapy with HCV protease inhibitor, SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2009
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Schering-Plough
- 29 Oct 2009 Substudy results assesing antiretroviral resistance presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Dec 2008 New trial record.